warts%20-%20anogenital
WARTS - ANOGENITAL
Anogenital warts (condylomas) are caused by human papillomavirus (HPV) with >90% of the lesions caused by genotypes 6 & 11.
Patients who present with visible warts may also be infected with high-risk HPVs (eg types 16 & 18) which can cause subclinical lesions that are associated with intraepithelial neoplasia, cervical cancer and anogenital cancer.
Many HPV infections are subclinical, transient, and clear spontaneously within 12 months but may also remain latent and reactivate after several years.

Prevention

  • Condoms provide limited protection against genital warts, cervical intraepithelial neoplasia (CIN) II and CIN III
  • Frequent cervical screening should start at appropriate age and be based on cytology since not all human papillomavirus (HPV) infection produce cervical cancer

Vaccines

  • Safe and highly effective in preventing HPV
  • Ideally given prior to sexual activity or exposure to the virus
  • Stable protection has been observed for 5 years
  • Not recommended for use during pregnancy

Quadrivalent HPV Vaccine

  • Contains HPV capsids of type 16, 18, 6 and 11
  • Studies show efficacy in preventing type-specific HPV infection

9-valent HPV Vaccine

  • Contains HPV types 6, 11, 16 and 18 similar to the quadrivalent HPV vaccine but also has five additional types: 31, 33, 45, 52 and 58  
  • For prophylactic use only and has no effect on active HPV infections or established disease

Follow Up

  • Patients undergoing therapy should be advised to return weekly for treatment until all the warts are removed in order to:
    • Monitor response to therapy, ie treatment response is mostly noted within 3 months of therapy
    • Assess need for changes in treatment modalities
    • Evaluate recurrence
    • Assess need for specialist referral
  • Patients whose original lesions have responded well to treatment but in whom new lesions are developing can continue with current regimen
  • Change in therapy is indicated if the patient is not tolerating current therapy, with severe side effects or <50% response to current treatment after 16 weeks for Imiquimod and 6 weeks for other modalities
  • Patients concerned about recurrence may be evaluated 3 months after successful treatment
    • Relapses should be treated according to the lesion types

Specialist Referral

  • Consider specialist referral in the following patients:
    • Large-volume disseminated disease
    • Intractable lesions
    • Immunocompromised patients
    • Pregnant patients
    • Children
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
02 Nov 2017
In this issue of MIMS Anti-Infective Supplement, we bring you clinical updates related to combating infectious diseases, and also a symposium highlight in conjunction with the launch of ceftolozane/tazobactam (Zerbaxa; Merck Sharp & Dohme Sdn Bhd) in Malaysia. 
15 Nov 2017
New drug applications approved by US FDA as of 1 - 15 November 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Jairia Dela Cruz, 16 Nov 2017
Treatment with a ribavirin-free regimen of coformulated glecaprevir plus pibrentasvir appears to yield a high rate of sustained virologic response in hepatitis C virus-infected patients with advanced chronic kidney disease, while having an acceptable safety profile, according to the EXPEDITION-4 trial.
Roshini Claire Anthony, 17 Nov 2017

Use of the blood infection biomarker procalcitonin as a guide to prescribing antibiotics led to lower antibiotic exposure and side effects, as well as a lower mortality rate in individuals with acute respiratory infections, based on findings of a meta-analysis.